Adjuvant used for vaccine and application thereof

An adjuvant and vaccine technology, applied in the direction of medical preparations with non-active ingredients, medical preparations containing active ingredients, antibody medical ingredients, etc., can solve potential safety hazards, can not meet the needs of new vaccine development, toxic and side effects and other problems

Active Publication Date: 2016-12-07
PU LIKE BIO ENG
View PDF27 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are many types of immune adjuvants studied, such as aluminum gel, oil adjuvant, Freund's adjuvant, microorganisms and their metabolites, nucleic acids and their analogs, cytokines, liposomes, etc. (Dey AK, Srivastava IK.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Expert review of vaccines,2011,10:227-251), but it is difficult to be practically applied due to some inevitable defects such as different degrees of toxic side effects or safety hazards (Mbow ML Batista-Duharte A, Lindblad EB, Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms.Toxicology letters,2011,203(2):97-105), these adjuvants are far from meeting the needs of new vaccine development
In particular, a large number of clinical immunization trials believe that aluminum colloidal adjuvant has some problems: (1) it has a strong stimulating effect on Th2-mediated humor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adjuvant used for vaccine and application thereof
  • Adjuvant used for vaccine and application thereof
  • Adjuvant used for vaccine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] The preparation of embodiment 1 antigen

[0051] 1.1 Preparation of porcine circovirus antigen

[0052] According to Chinese patent CN103083655A, porcine circovirus type 2 SH strain virus liquid was prepared and the virus liquid content was measured, and the result: the content of porcine circovirus type 2 SH strain was 5×10 6.0 TCID 50 / ml; and inactivate the virus liquid and detect the inactivation effect with the indirect immunofluorescence method IFA, the result: no green PCV2 positive cells are produced, indicating that the porcine circovirus type 2 SH strain virus liquid is successfully inactivated.

[0053] 1.2 Preparation of Mycoplasma hyopneumoniae antigen

[0054] According to the Chinese patent CN103083655A, the bacterial liquid of Mycoplasma hyopneumoniae HN0613 strain was prepared and the content of bacterial liquid was determined, and the result: the content of Mycoplasma hyopneumoniae strain HN0613 was 1×10 9 CCU / ml; and inactivate and test the bacteri...

Embodiment 2

[0057] The preparation of embodiment 2 adjuvants

[0058] Aluminum glue: purchased from General Chemical, LLC of the United States HPA adjuvant.

[0059] Levamisole mother solution: The levamisole raw material purchased from Xi'an Saino Biotechnology Co., Ltd. was heated and dissolved into a 40 mg / ml solution, and sterilized by filtration to obtain a 40 mg / ml levamisole mother solution.

[0060] Sodium polyacrylate mother liquor: mix 1g sodium polyacrylate purchased from Shanghai Yiji Industrial Co., Ltd. with 100% distilled water, heat and boil until completely dissolved, then cool to room temperature, that is, configure a sodium polyacrylate mother liquor with a concentration of 10mg / ml, and Autoclave at 121°C for 30 minutes before use.

Embodiment 3

[0061] Preparation and animal test of embodiment 3 inactivated vaccine composition

[0062] 3.1 Preparation of inactivated vaccine composition

[0063] The antigen prepared in Example 1 and the adjuvant prepared in Example 2 were diluted with PBS solution, and each antigen solution after dilution was mixed with the final concentration of the adjuvant according to the components contained in the inactivated vaccine composition in Table 1, with 500 Stir at -800 rpm for 10-15 minutes, add 1% V / V of thimerosal (purchased from Sinopharm Chemical Reagent Co., Ltd.) solution before terminating the stirring, so that the final concentration does not exceed 1 / 10,000, fully shake Mix well, subpackage, and store at 2-8°C after subpackaging.

[0064]

[0065]

[0066] 3.2 Animal Test of Porcine Circovirus Antigen of Inactivated Vaccine Composition

[0067] Vaccines A1, A2, A3, A6, A7, A9, B1, B2, B3, B6, B7, B9 prepared in Example 3.1 and a reference vaccine control group (PCV2 vac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to view more

Abstract

The invention provides an adjuvant used for vaccine. The adjuvant comprises alumina gel, levamisole or its derivative, and also polyacrylate. The invention also discloses a vaccine composition containing the adjuvant and an application thereof. The adjuvant can be used as the adjuvant for inactivated vaccine, and also can be used for preparing protein stabilization liquid. The vaccine composition containing the adjuvant can generate humoral immunity for human body and can generate cellular immunity, and can generate good immune response under condition of low antigen content and single immune, and can stabilize protein, degradation and irreversible change cannot be generated.

Description

technical field [0001] The invention belongs to the technical field of veterinary biological products, and specifically relates to an adjuvant for enhancing antigen immune response, the adjuvant includes aluminum gel, levamisole or its derivatives, and polyacrylic acid salt, and is used in vaccine compositions and proteins , without producing toxicity or unwanted side effects in the subject. Background technique [0002] Bacterial, viral and parasitic infections are widespread in humans and animals, and diseases caused by these infectious agents are often resistant to antimicrobial therapy, leaving no effective treatment available. Therefore, more and more people use vaccinology to control infection, specifically through vaccination with live pathogens, inactivated pathogens or their products, or genetically engineered pathogen protein subunits to prepare vaccines to induce infection. specific immunity. However, certain antigens do not produce sufficient stimulation of the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/39A61K47/22A61P37/04
Inventor 张许科孙进忠王莹田克恭
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap